Experimental hookworm infection: a randomized placebo-controlled trial in asthma

J. R. Feary1, A. J. Venn1, K. Mortimer2, A. P Brown3, D. Hooi3, F. H. Falcone3, D. I. Pritchard3 and J. R. Britton1

1Division of Epidemiology and Public Health, University of Nottingham, Nottingham, UK, 2Division of Respiratory Medicine, University of Nottingham, Nottingham, UK and 3School of Pharmacy, University of Nottingham, Nottingham, UK

Summary

Background Epidemiological studies suggest that hookworm infection protects against asthma, and therefore that hookworm infection may have a direct or an indirect therapeutic potential in this disease. We now report the first clinical trial of experimental hookworm infection in people with allergic asthma.

Objectives To determine the effects of experimental hookworm infection in asthma.

Methods Thirty-two individuals with asthma and measurable airway responsiveness to adenosine monophosphate (AMP) were randomized and double blinded to cutaneous administration of either ten Necator americanus larvae, or histamine solution (placebo), and followed for 16 weeks. The primary outcome was the change in provocation dose of inhaled AMP required to reduce forced expiratory volume in 1 s by 20% (PD20AMP) from baseline to week 16. Secondary outcomes included change in several measures of asthma control and allergen skin sensitivity and the occurrence of adverse effects.

Results Mean PD20AMP improved in both groups, more in the hookworm [1.49 doubling doses (DD)] than the placebo group (0.98 DD), but the difference between groups was not significant (0.51 DD; 95% confidence interval: /C0 1.79 to 2.80; /P = 0.65). There were no significant differences between the two groups for other measures of asthma control or allergen skin sensitivity. Infection was generally well tolerated.

Conclusions Experimental infection with ten hookworm larvae in asthma did not result in significant improvement in bronchial responsiveness or other measures of asthma control in this study. However, infection was well tolerated and resulted in a non-significant improvement in airway responsiveness, indicating that further studies that mimic more closely natural infection are feasible and should be undertaken.

Keywords airway responsiveness, asthma, helminth, hookworm, intervention, Necator americanus, randomized-controlled trial

Submitted 19 August 2009; revised 11 October 2009; accepted 4 November 2009

Introduction

Asthma is one of the commonest chronic diseases of developed countries, but despite significant investment, research into the aetiology of asthma has yet to identify the major avoidable causes, and the available treatments remain poorly effective in around 10% of patients [1]. New approaches to the prevention and treatment of asthma are urgently needed. There is now substantial epidemiological evidence that intestinal parasite infection in general, and hookworm infection in particular, may protect against wheeze, asthma and other allergic disease [2, 3]. These findings raise the possibility that experimentally induced parasite infections may be able to contribute, directly or indirectly, to the development of new strategies for the management of asthma.

We have previously reported two studies carried out in preparation for clinical trials of the effect of experimental hookworm infection in asthma. The first was a dose-ranging study in normal volunteers [4], which found that infection with ten Necator americanus larvae established a level of intensity of infection (>50 eggs/g feces), as identified in our previous epidemiological work, to be strongly associated with protection against asthma symptoms [5]. The
was below normal reference levels or they did not have a positive skin test response to at least one allergen.

All eligible participants had their inhaler technique reviewed and were provided with a miniWright peak flow meter (EU scale). Instruction on peak expiratory flow (PEF) measurement was given and inhaler technique was optimized. For the duration of the study, participants were asked to continue their usual asthma medication and to use short-acting inhaled \( \beta_2 \)-agonists for a relief of asthma symptoms.

**Randomization**

Participants were seen after a 2-week run-in period for concealed randomization to active or placebo infection, allocated in blocks of four according to a computer-generated random code. Larvae were obtained from a healthy human source known to be negative for hepatitis B and C and human immunodeficiency virus, as described previously [11]. Two hundred microlitres of water containing ten *N. americanus* larvae (active infection) or 200 \( \mu \)L histamine dihydrochloride solution (1.7 mg/mL) (placebo) was then administered to an area of skin on the forearm and covered with gauze and water-tight adhesive dressing for 24 h. To ensure the clinical researcher carrying out the protocol measures remained blind to treatment allocation, infection solutions were administered by an independent member of the research team not involved in the study measurements.

**Follow-up**

After randomization, participants attended study visits every fortnight for 8 weeks, and at 12 and 16 weeks. Our original protocol specified 12 weeks follow-up, but because the eosinophilia we observed in the safety study was still decreasing at 12 weeks [6] before commencing the present study, we elected to increase follow-up to 16 weeks. At each study visit, the Juniper AQLQ was completed, venous blood was taken for the same tests as at the screening visit and a stool sample, collected within the preceding 24 h, was provided for quantification of egg burden, as described previously [4]. PD_{20AMP} was measured, and if after enrolment in the study, participants no longer responded with a 20% reduction in FEV\(_1\), at below the maximum administered dose of AMP, a censored value of 1888 \( \mu \)M was assigned, which is one doubling dose higher than the maximum dose of AMP administered [12, 13]. An additional full blood count test was carried out 3 weeks after randomization to coincide with the expected time of onset of hookworm-associated eosinophilia [4, 6]. For the duration of the study, including the 2-week run-in period before randomization, participants completed a daily diary, recording twice-daily PEF (best of three attempts), twice-daily asthma symptom scores on a scale of 0 (no symptoms) to 5 (maximal symptoms), use of
reliever medication and scores for a range of pre-determined symptoms potentially attributable to hookworm infection on a scale from 0 (none) to 10 (maximum possible severity). Allergen skin tests were repeated at the final visit (week 16) and participants were then unblinded by the researcher who administered the infection or placebo at their randomization visit. Those in the hookworm group were supplied with mebendazole 100 mg twice a day for 3 days to eradicate the infection; stool egg counts and blood eosinophil counts were checked fortnightly in those completing therapy until egg counts were zero and eosinophils had returned to within $0.2 \times 10^3$/L of their screening value.

**Safety and Ethics**

Data on adverse effects and haemoglobin, eosinophil and serum albumin levels were monitored regularly by the trial statistician and a data monitoring committee. The study was approved by the Nottingham Research Ethics Committee, the Research and Development Department at Nottingham University Hospitals NHS Trust and registered with the Clinical Trials register (reference NCT00469989).

**Data analysis**

The primary outcome was the change in PD$_{20}$AMP from baseline (mean of screening and randomization visit values) to the week 16 (final visit) value expressed in doubling doses. Secondary outcome measures of asthma control were determined for each 2-week period of the study and comprised PEF variability (two-lowest percent mean [14]), percentage of symptom-free days and nights (determined using the twice daily asthma-control symptoms scores), and percentage of reliever inhaler-free days and nights and Juniper AQLQ scores [10]. We plotted these variables over time to assess any trend, and then computed the difference between baseline (run-in period or for Juniper AQLQ, the mean of the screening and randomization visits) and the end of the study (weeks 15 and 16). We also computed area under the curve (AUC) (GraphPad Prism 5, GraphPad Software Inc., San Diego, CA, USA) using the period weeks 5–16 as an alternative summary variable for PD$_{20}$AMP and each asthma control measure to ensure that we did not miss an effect if the measurements taken at the end of the study had been spurious. Change in allergen skin sensitization (mm) was calculated as the difference between the baseline and week-16 saline-adjusted results. Mean daily symptom scores for adverse effects potentially attributable to the hookworm infection were compared over the entire 16 weeks and also for a pre-determined ‘high-risk’ period chosen, observed as the period during which the symptoms were most likely to occur in our previous studies [4, 6].

The two groups were compared using the independent samples t-test for all variables with the exception of the adverse effects symptoms and AUC variables, which were not normally distributed, could not be transformed and were therefore compared using the Mann–Whitney U-test. As this was a relatively small trial, we explored whether adjusting for potential confounders (variables listed in Table 1) using multiple linear regression affected the results. We repeated the analyses using data from just the first 4 weeks after randomization to determine whether there was evidence of exacerbation of asthma during the phase of larval pulmonary migration.

Three sensitivity analyses for each outcome were also performed excluding participants who: (i) breached the protocol, (ii) had $<75\%$ of potentially available data complete for the outcome variable and (iii) were infected with hookworm but did not have a positive stool culture for larvae at week 16. All data were analysed using STATA 10 SE (STATA Corp., College station, TX, USA).

**Sample size calculation**

Our pre-study sample size calculation revealed a sample size of 30 (15 in each group) would provide 80% power to detect one doubling dose difference in our primary outcome, change in PD$_{20}$AMP, between hookworm and placebo groups assuming a standard deviation of approximately one doubling dose (DD).

### Table 1. Baseline characteristics of participants completing the study

| Demographics | Hookworm ($n = 16$) | Placebo ($n = 16$) |
|--------------|---------------------|---------------------|
| Gender       |                     |                     |
| Male         | 8 (50%)             | 9 (56%)             |
| Female       | 8 (50%)             | 7 (44%)             |
| Age (years)  |                     |                     |
| Mean (SD)    | 40.9 (10.7)         | 39.8 (15.2)         |
| Body mass index (kg/m$^2$) | 25.6 (23.5, 26.8) | 26.9 (23.8, 29.6) |
| Deprivation score* | 15.6 (9.0, 28.3) | 13.3 (7.0, 30.3) |
| Smoking status |                   |                     |
| Never        | 10 (63%)            | 11 (69%)            |
| Ever         | 6 (38%)             | 5 (31%)             |
| Asthma mediation |               |                     |
| Daily inhaled corticosteroid dose |                 |                     |
| $<500$ mcg/day | 10 (63%) | 9 (56%) |
| $>500$ mcg/day | 6 (38%) | 7 (44%) |
| Past oral steroid usage |               |                     |
| No           | 8 (50%)             | 4 (25%)             |
| Yes – not in last 2 years | 5 (31%) | 8 (50%) |
| Yes – in last 2 years | 3 (19%) | 4 (25%) |
| Daily long-acting $\beta_2$-agonist usage |               |                     |
| None         | 11 (69%)            | 9 (56%)             |
| Some         | 5 (31%)             | 7 (44%)             |

*Using index of multiple deprivations [15].

IQR, interquartile range; SD, standard deviation.
Results

Thirty-four participants were recruited between December 2006 and June 2007 with 17 allocated to each intervention. Two participants withdrew before our primary end-point could be measured, that is, before parasite maturation was complete (one from the placebo group on day 6 due to psychological problems, and one from the hookworm group on day 34 due to abdominal pain); they were excluded from further analysis (Fig. 1). Baseline characteristics of the two study groups were similar with respect to gender, age, body mass index, smoking history, index of multiple deprivation [15], use of asthma medication (Table 1), bronchial responsiveness (PD_{20AMP}), lung function (percentage predicted FEV₁ and PEF variability), Juniper AQLQ score and symptom-free and reliever-inhaler-free days and nights (Table 2).

Primary outcome

PD_{20AMP} improved relative to baseline in 11 of the 16 participants finishing the study who received hookworm (69%) and in eight who received placebo (50%). Mean PD_{20AMP} improved in the hookworm group by 1.49 (SD 2.00) DD and in the placebo group by 0.98 (4.02) DD, but the mean difference between these changes was not statistically significant [0.51 DD; 95% confidence interval (CI) −1.79 to 2.80; P = 0.65, Table 3].

Secondary outcomes

Juniper AQLQ and self-reported asthma symptom-free days and nights scores improved in both groups, more in the placebo group than the hookworm group (change in Juniper scores 15.34 vs. 10.66; symptom-free days 13.31% vs. 8.29%; symptom-free nights 12.63% vs. 9.71%), but neither this nor any other secondary outcome change differed significantly between groups (Table 3).

For both primary and secondary outcomes, there were no significant differences between the groups when we adjusted for potential confounders, carried out the sensitivity analyses or when outcomes were assessed using AUC (weeks 5–16) instead of change from the beginning to the end of the study (data not shown).

Adverse effects

Localized skin redness and itching at the site of infection were reported in the hookworm group, particularly between 1 and 21 days after infection. Median daily scores of gastrointestinal symptoms were generally low but tended to be slightly higher in the hookworm than placebo group, significantly so for abdominal pain, and additionally for loss of appetite and nausea during the high-risk period (days 29–112; Table 4). There was no evidence to suggest a worsening of asthma during the first 4 weeks of the study. No clinically important change was observed in either of the groups in haemoglobin or serum albumen.

Confirmation of hookworm infection

All participants who received hookworm infection had a rise in peripheral blood eosinophil counts beginning around day 21 and peaking at 1.4–8.5×10⁹/L between...
Table 2. Baseline clinical measures

| Measure                                                                 | Hookworm (n = 16) | Placebo (n = 16) |
|------------------------------------------------------------------------|-------------------|-----------------|
| **Lung function [mean (SD)]**                                          |                   |                 |
| % predicted FEV₁ at screening visit                                    | 83.38 (15.77)     | 87.06 (23.13)   |
| % predicted FEV₁ at randomization                                     | 80.25 (17.98)     | 85.94 (18.37)   |
| **Bronchial responsiveness [median (IQR)]**                           |                   |                 |
| PD₂₀ AMP at screening visit                                           | 2.34 (0.78, 7.30) | 3.76 (1.49, 7.52) |
| PD₂₀ AMP at randomization                                             | 4.10 (1.53, 11.26) | 6.98 (1.93, 17.22) |
| **Skin sensitization to allergen at the screening visit [weal size in mm; (mean (SD)]** |                   |                 |
| Grass                                                                  | 5.13 (3.00)       | 5.31 (5.22)     |
| Cat fur                                                                | 4.25 (2.58)       | 3.91 (3.72)     |
| *Dermatophagoides pteronyssinus*                                       | 6.53 (3.29)       | 6.38 (4.36)     |
| **Juniper AQLQ scores [median (IQR)]**                                |                   |                 |
| Juniper score at screening visit for run-in period                    | 193.00 (186.00, 212.50) | 175.00 (154.00, 203.00) |
| Juniper score at randomization for run-in period                      | 200.00 (186.50, 212.00) | 186.50 (174.00, 209.00) |
| **PEF variability [median (IQR)]**                                     |                   |                 |
| PEF variability (%) during run-in period                              | 91.99 (87.96, 93.10) | 91.68 (85.62, 94.25) |
| % symptom-free days/nights [median (IQR)]                              | 46.43 (8.12, 96.43) | 85.71 (57.69, 92.58) |
| Change in skin sensitization to grass (final visit – screening visit) | -0.59 (2.42) -0.19 (2.37) | -0.41 -2.14, 1.32 | 0.63 |
| Change in skin sensitization to cat fur (final visit – screening visit) | 0.19 (1.74) 0.03 (1.63) | 0.16 -1.06, 1.37 | 0.79 |
| Change in skin sensitization to *Dermatophagoides pteronyssinus* (final visit – screening visit) | -0.66 (1.46) -0.19 (2.45) | -0.47 -1.94, 1.00 | 0.52 |

* n = 13.
† n = 15.
‡ Maximum score of 224 where the higher scores indicates better quality of life.
§ PEF variability: a value of 100 indicates no variability, i.e. perfect control.

% predicted FEV₁, percentage predicted forced expiratory volume in 1 s; AQLQ, Asthma Quality of Life Questionnaire; IQR, inter-quartile range; PD₂₀AMP (DD), provocation dose of adenosine monophosphate to reduce forced expiratory volume in 1 s by 20% in doubling doses; PEF, peak expiratory flow; SD, standard deviation.

Table 3. Change in asthma and allergic outcomes from the baseline to the end of the study

| Outcome                                                                 | Hookworm (n = 16) | Placebo (n = 16) | Difference in means | 95% CI     | P-value* |
|------------------------------------------------------------------------|-------------------|-----------------|--------------------|-----------|----------|
| **Bronchial responsiveness (DD)**                                       |                   |                 |                    |           |          |
| Change in PD₂₀AMP (DD) (final visit – mean of randomization and screening visits) | 1.49 (2.00)       | 0.98 (4.02)     | 0.51               | -1.79, 2.80 | 0.65     |
| **Skin sensitivity (mm)**                                              |                   |                 |                    |           |          |
| Change in skin sensitization to grass (final visit – screening visit)  | -0.59 (2.42) -0.19 (2.37) | -0.41 -2.14, 1.32 | 0.63               |           |          |
| Change in skin sensitization to cat fur (final visit – screening visit) | 0.19 (1.74) 0.03 (1.63) | 0.16 -1.06, 1.37 | 0.79               |           |          |
| Change in skin sensitization to *Dermatophagoides pteronyssinus* (final visit – screening visit) | -0.66 (1.46) -0.19 (2.45) | -0.47 -1.94, 1.00 | 0.52               |           |          |
| **Juniper AQLQ scores**                                                |                   |                 |                    |           |          |
| Change in Juniper score (final visit – mean of screening and randomization visits) | 10.66 (14.08) 15.34 (22.41) | -4.69 -18.20, 8.82 | 0.48               |           |          |
| **PEF variability [median (IQR)]**                                     |                   |                 |                    |           |          |
| Change in PEF variability (%) (final 2 weeks – run-in period)          | 1.03 (6.17) -1.21 (7.17) | 2.23 -2.60, 7.06 | 0.35               |           |          |
| Change in % symptom-free days (final 2 weeks – run-in period)          | 8.43 (39.67) 12.59 (46.39) | -4.16 -35.32, 27.01 | 0.79               |           |          |
| Change in % symptom-free nights (final 2 weeks – run-in period)        | 9.05 (32.50) 12.72 (48.98) | -3.66 -33.68, 26.35 | 0.80               |           |          |
| Change in % reliever free days (final 2 weeks – run-in period)         | 0.37 (24.87) 1.39 (34.46) | -1.03 -22.72, 20.67 | 0.92               |           |          |
| Change in % reliever free nights (final 2 weeks – run-in period)       | 0.01 (21.49) 3.59 (27.17) | -3.60 -21.28, 14.09 | 0.68               |           |          |

* P-value for independent samples t-test.
† Higher scores indicate best the quality of life.
‡ PEF variability value of 100 indicates no variability, i.e. perfect control.
95% CI, 95% confidence interval; AQLQ, Asthma Quality of Life Questionnaire; DD, doubling dose; PEF, peak expiratory flow; PD₂₀AMP (DD), provocation dose of adenosine monophosphate to reduce forced expiratory volume in 1 s by 20% in doubling doses; SD, standard deviation.

© 2009 Blackwell Publishing Ltd, *Clinical & Experimental Allergy*, 40: 299–306
days 42 and 84. Eosinophil counts in the hookworm group were all higher at the end of the study than at the time of infection (Fig. 2). Nine of the 16 participants who received hookworm and completed the study had eggs detected in their stool samples, appearing by week 6 in three and week 8 in six participants. At the final visit, stool cultures were positive for nine participants, eight of whom had had detectable eggs in their stool samples previously. All positive egg counts at this final visit were between 95 and 213 eggs/g feces.

Assessment of participant blinding

At the end of the study, 11 participants in the hookworm group thought correctly that they had received infection (due to visible portals of entry on the skin and gastrointestinal disturbance); five did not know. Of those who received the placebo, eight correctly thought they had been allocated the placebo, two incorrectly thought they had received hookworm and six did not know. Thirteen out of 16 participants who received hookworm and completed the study elected to keep their infection.

Discussion

This is the first reported intervention study of experimental hookworm infection in people with asthma. We found that the infection improved BHR by half a doubling dose more than the placebo group, although the confidence interval was wide and the difference between the groups was not significant. Our findings provide proof of concept that trials of experimental hookworm infection are feasible, well...

---

Table 4. Symptoms potentially attributable to hookworm infection experienced during the 16-week study period and high-risk period for participants with and without infection

| Symptoms               | Daily score (scale 0–10) over total 16-week period | Daily score (scale 0–10) over high-risk period | P-value*
|------------------------|---------------------------------------------------|-----------------------------------------------|---
|                        | Hookworm Median (range)                            | Placebo Median (range)                        | Difference in medians |
| Localized skin itching | 0.28 (0.04, 2.17)                                  | 0 (0, 0.16)                                   | 0.28 <0.001*          |
| Localized skin redness | 0.45 (0.06, 2.13)                                  | 0 (0, 0.23)                                   | 0.45 <0.001*          |
| Nausea                 | 0.08 (0, 1.51)                                     | 0.01 (0, 0.46)                                | 0.07 0.17             |
| Diarrhoea              | 0.06 (0, 2.03)                                     | 0.06 (0, 0.52)                                | 0.00 0.69             |
| Abdominal pain         | 0.23 (0, 2.05)                                     | 0.03 (0, 1.04)                                | 0.20 0.02*            |
| Flatulence             | 0.24 (0, 5.43)                                     | 0.12 (0, 1.65)                                | 0.12 0.25             |
| Indigestion            | 0.11 (0, 2.56)                                     | 0.01 (0, 0.43)                                | 0.10 0.31             |
| Loss of appetite       | 0.08 (0, 0.42)                                     | 0 (0, 1.18)                                   | 0.08 0.08             |
| Tiredness              | 0.18 (0, 4.47)                                     | 0.67 (0, 5.00)                                | –0.49 0.51            |
|                        |                                                    |                                               |                        | 1.40 (0.24, 4.43)      | 0 (0, 0.67) | 1.40 <0.001* |
|                        |                                                    |                                               |                        | 2.18 (0.33, 4.19)      | 0 (0, 1.19) | 2.18 <0.001* |
|                        |                                                    |                                               |                        | 0.05 (0, 1.84)         | 0 (0, 0.61) | 0.05 0.04*   |
|                        |                                                    |                                               |                        | 0.04 (0, 1.90)         | 0.05 (0, 0.29) | –0.01 0.85 |
|                        |                                                    |                                               |                        | 0.30 (0, 2.59)         | 0.01 (0, 0.92) | 0.29 0.02* |
|                        |                                                    |                                               |                        | 0.20 (0, 6.07)         | 0.05 (1, 1.77) | 0.15 0.23 |
|                        |                                                    |                                               |                        | 0.07 (3, 0.03)         | 0 (0, 1.19) | 0.07 0.24   |
|                        |                                                    |                                               |                        | 0.08 (0, 0.38)         | 0 (0, 0.83) | 0.08 0.04*  |
|                        |                                                    |                                               |                        | 0.20 (0, 10)           | 0.36 (5, 5.52) | –0.16 0.52 |

1High-risk periods: localized skin symptoms (days 1–21), gastrointestinal symptoms and tiredness (days 29–112).

*P-value <0.05.

†P-value for Mann–Whitney–U-test.

---

Fig. 2. Peripheral blood eosinophil counts in participants randomized to (a) hookworm and (b) placebo.
tolerated and, because the majority of participants chose to retain their infection after completion of the trial, that sustained infection is acceptable to patients.

The hypothesis tested in this study arises from multiple epidemiological studies demonstrating an inverse relation between helminth infection, especially hookworm, and both atopy and asthma [2, 3]. Previous intervention studies relevant to this hypothesis are limited to eradication studies, mostly performed in areas where hookworm was not the predominant endemic infection, and have produced mixed findings. Two studies found no difference in wheeze [16] or asthma [17] after antihelmintic therapy when compared with controls. Conversely, another study reported a temporary improvement in asthma after albendazole, although this was not statistically compared with the placebo group [18]. Effects on atopy after antihelmintic therapy are more consistent with three studies showing a clear increase in atopic response to allergen skin sensitization after treatment compared with controls [17, 19, 20] with a particularly strong effect for those with both hookworm and Ascaris infection [odds ratio (OR) 4.9, 95% CI: 1.48–16.19] [17]. However, other studies have found the effect of antihelmintic treatment when compared with controls to be associated with a reduction in atopy [19] or to have no effect [16, 21].

A number of factors may explain why our trial did not demonstrate a statistically significant effect on BHR. It may be a false negative finding due to insufficient statistical power, particularly because the level of variability observed in our primary outcome, the change in PD20AMP, was greater than anticipated (SD 2.00 and 3.99 DD in hookworm and placebo groups, respectively). Blinding of treatment allocation was successful for those who received placebo and the clinical researcher who conducted the study visits and analysed the data, but less so for participants who received hookworm. However, we think it is unlikely that this appreciably affected our primary outcome, because this was based on objective measures of airway responsiveness. There is a possibility of random error in the PD20AMP values, and to reduce the impact of spurious results at randomization, we used the mean of the randomization and screening visits values to define the baseline PD20AMP, in accordance with our protocol. We did, however, observe a tendency for values to be higher at randomization than screening in both groups, which we believe is most likely due to a combination of improvement in inhaler technique and compliance with asthma treatment following education at the screening visit. However, we found no significant difference in change in PD20AMP between the groups regardless of whether values from the screening visit, randomization visit or the mean of the two was used as the baseline value. While people volunteering to take part in a study of experimental hookworm infection (or indeed any clinical trial) may not be representative of the asthma population in general, we have no reason to suspect that any such differences would interact with the clinical effect of hookworm infection.

Our previous studies showed 10 larvae to be effective in establishing infection to an intensity producing >50 eggs/g of feces [4, 6], but in the present study, eggs were not observed at any time in feces from several participants. Nevertheless, all infected participants exhibited marked elevation of peripheral blood eosinophilia, suggesting that those with no eggs in feces were infected with non-fecund or same-sex organisms. It is also plausible that the presence of allergic asthma reduces hookworm fecundity [22]. Another possibility is that the dose administered was not adequate to induce an immunological response of sufficient strength and type to be beneficial. We know from our study in people with allergic rhinoconjunctivitis that 10 infective larvae are sufficient to induce a natural immune phenotype with a weak indication of the establishment of an immune modulatory profile [7]. However, immune modulation may require further boosting to generate clinical benefit. Boosting could be achieved through the administration of repeated low-dose infections or through an increase in dosage. The former approach is probably more realistic, to avoid the undesirable adverse effects experienced with higher doses [4] and may mimic the pattern of natural and reportedly beneficial infection more closely. In addition, all participants in this study were receiving inhaled corticosteroid treatment, which may have inhibited the beneficial immunological shift induced by worms (such as the generation of regulatory T cell populations,) potentially conducing to therapeutic benefit and which has been linked to the alleviation of autoimmune disease in animal models and people with multiple sclerosis [23]. It is also possible that our study is negative because there is no true effect of hookworm infection in asthma, and that epidemiological associations observed previously have arisen from bias or confounding. However, given the consistency of the epidemiological evidence [3], we would propose that further studies of this hypothesis are both indicated and worth pursuing. Finally, the epidemiological findings may arise from reverse causation, whereby individuals with allergies are less likely to establish hookworm infection, but the high level of infection in our previous study, carried out in allergic individuals, argues against this [5].

In conclusion, our work at this juncture does not prove or refute the hypothesis that hookworm infection may protect against asthma, but establishes that trials of this intervention are feasible to pursue in clinical populations. Further studies of repeated low-dose infections, with longer periods of follow-up, and if possible, measures to ensure greater blinding of participants, are now indicated. Immunological monitoring for the presence of regulatory T cell populations and cytokines and further assessment of the potential for polyclonal IgE to moderate allergic responses, should proceed in parallel, although recent
field work suggests that the latter mechanism may not be operating in necatoriasis [24].

Acknowledgements

This work was funded by the Wellcome Trust (GR076306/2/04/2, GR065978MA). We thank Jack Gibson for assistance with data management; Zara Pogson, Rachael Murray and Marilyn Anthoniak for help with study visits; and our Trial Safety Steering Committee members Professor A. Knox, Dr R.G. Jenkins, Dr T. Coleman and Professor S. Lewis.

Conflict of interest: D. I. P. and F. H. F. are inventors on patents supporting the use of molecules derived from helminths as immune modulatory agents.

References

1 Holgate ST, Polosa R. The mechanisms, diagnosis, and management of severe asthma in adults. *Lancet* 2006; 368:780–93.
2 Flohr C, Quinnell RJ, Britton J. Do helminth parasites protect against atopy and allergic disease? *Clin Exp Allergy* 2009; 39:20–32.
3 Leonardi-Bee J, Pritchard D, Britton J. Asthma and current intestinal parasite infection: systematic review and meta-analysis. *Am J Respir Crit Care Med* 2006; 174:514–23.
4 Mortimer K, Brown A, Feary J et al. Dose-ranging study for trials of therapeutic infection with *Necator Americanus* in humans. *Am J Trop Med Hyg* 2006; 75:914–20.
5 Scrivener S, Yemanbeheran H, Zebenigus M et al. Independent effects of intestinal parasite infection and domestic allergen exposure on risk of wheeze in Ethiopia: a nested case-control study. *Lancet* 2001; 358:1493–9.
6 Feary J, Venn A, Brown A et al. Safety of hookworm infection in individuals with measurable airway responsiveness: a randomised placebo-controlled feasibility study. *Clin Exp Allergy* 2009; 39:1060–8.
7 Blount D, Hooi D, Feary J et al. Immunological profiles of subjects recruited for a randomised, placebo controlled clinical trial of hookworm infection. *Am J Trop Med Hyg* 2009; 81:911–6.
8 Crapo RO, Casaburi R, Coates AL et al. Guidelines for methacholine and exercise challenge testing-1999. This official statement of the American thoracic society was adopted by the ATS board of directors, July 1999. *Am J Respir Crit Care Med* 2000; 161:309–29.
9 Zawodniak A, Kupczyk M, Gorski P, Kuna P. Comparison of standard and modified SPT method. *Allergy* 2003; 58:257–9.
10 Juniper EF, Guyatt GH, Epstein RS, Ferrie PJ, Jaeschke R, Hiller TK. Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials. *Thorax* 1992; 47:76–83.
11 Kumar S, Pritchard DI. The partial characterization of proteases present in the excretory/secretory products and exsheathing fluid of the infecitive (L3) larva of *Necator Americanus*. *Int J Parasitol* 1992; 22:563–72.
12 Higgins BG, Britton JR, Chinn S et al. Comparison of histamine and methacholine for use in bronchial challenge tests in community studies. *Thorax* 1988; 43:605–10.
13 Piccillo G, Caponnetto P, Barton S et al. Changes in airway hyperresponsiveness following smoking cessation: comparisons between Mch and AMP. *Respir Med* 2008; 102:256–65.
14 Siersted HC, Hansen HS, Hansen HS, Hyldenbrandt N, Mostgaard G, Oxhoj H. Evaluation of peak expiratory flow variability in an adolescent population sample. The Odense schoolchild study. *Am J Respir Crit Care Med* 1994; 149 (Part 1):598–603.
15 The English Indices of Deprivation. 2007. Available at http://www.communities.gov.uk/publications/communities/indices-deprivation07 (accessed 28 March 2008).
16 Cooper PJ, Chico ME, Vaca MG et al. Effect of albendazole treatments on the prevalence of atopy in children living in communities endemic for geohelminth parasites: a cluster-randomised trial. *Lancet* 2006; 367:1598–603.
17 Flohr C, Tuyen LN, Quinnell RJ et al. Reduced helminth burden increases allergic skin sensation but not clinical allergy: a randomized, double-blind, placebo-controlled trial in Vietnam. *Clin Exp Allergy* 2009 September 15; [epub ahead of print].
18 Lynch NR, Palenque M, Hagel I, DiPrisco MC. Clinical improvement of asthma after anthelminthic treatment in a tropical situation. *Am J Respir Crit Care Med* 1997; 156:50–4.
19 Lynch NR, Hagel I, Perez M, Di Prisco MC, Lopez R, Alvarez N. Effect of anthelminthic treatment on the allergic reactivity of children in a tropical slum. *J Allergy Clin Immunol* 1993; 92:404–11.
20 van den Biggelaar AH, Rodrigues LC, van Ree R et al. Long-term treatment of intestinal helminths increases mite skin-test reactivity in gabonese schoolchildren. *J Infect Dis* 2004; 189:892–900.
21 Elliott AM, Mpairwe H, Quigley MA et al. Helminth infection during pregnancy and development of infantile eczema. *JAMA* 2005; 294:2032–4.
22 Pritchard DI, Quinnell RJ, Walsh EA. Immunity in humans to *Necator Americanus*: IgE, parasite weight and fecundity. *Parasite Immunol* 1995; 17:71–5.
23 Correale J, Farez M. Association between parasite infection and immune responses in multiple sclerosis. *Ann Neurol* 2007; 61:97–108.
24 Pritchard DI, Hooi DS, Brown A, Bockarie MJ, Caddick R, Quinnell RJ. Basophil competence during hookworm (*Necator Americanus*) infection. *Am J Trop Med Hyg* 2007; 77:860–5.